by | Apr 14, 2024 | Publications
Ann Saudi Med. 2024 Mar-Apr;44(2):93-103. doi: 10.5144/0256-4947.2024.93. Epub 2024 Apr 4. ABSTRACT BACKGROUND: Multiple myeloma (MM) represents the second most common hematologic malignancy (15%). Induction with bortezomib, cyclophosphamide, and dexamthasone VCd (d:...
by | Apr 13, 2024 | Publications
Medicine (Baltimore). 2024 Apr 12;103(15):e37580. doi: 10.1097/MD.0000000000037580. ABSTRACT In this research, it was aimed to evaluate effects of methane emissions on multiple myeloma related mortality rates. Two countries in Europe (Germany and Netherlands) and 1...
by | Apr 12, 2024 | Publications
Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27314. Online ahead of print. ABSTRACT In view of the increasing data evaluating carfilzomib-based induction for newly-diagnosed multiple myeloma (NDMM), we conducted a systematic review and meta-analysis comparing the...
by | Apr 12, 2024 | Publications
Expert Rev Anticancer Ther. 2024 Apr 12. doi: 10.1080/14737140.2024.2343114. Online ahead of print. ABSTRACT INTRODUCTION: The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome...
by | Apr 12, 2024 | Publications
Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):170-177. doi: 10.3760/cma.j.cn121090-20230810-00058. ABSTRACT Objective: To investigate the prognostic value of the Second Revision of the International Staging System (R2-ISS) in patients with newly diagnosed multiple...
by | Apr 12, 2024 | Publications
Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):203-208. doi: 10.3760/cma.j.cn121090-20230728-00036. ABSTRACT With the rapid iteration of multiple myeloma therapeutics over the last two decades, as well as increasing remission rates and depth of remission in patients,...
